Analysts See $0.50 EPS for Merit Medical Systems, Inc. (MMSI)

Merit Medical Systems, Inc. (NASDAQ:MMSI) Logo
Investors sentiment increased to 1.27 in Q1 2019. Its up 0.22, from 1.05 in 2018Q4. It increased, as 15 investors sold Merit Medical Systems, Inc. shares while 80 reduced holdings. 35 funds opened positions while 86 raised stakes. 50.57 million shares or 1.22% less from 51.20 million shares in 2018Q4 were reported.
Wells Fargo & Mn has 700,827 shares for 0.01% of their portfolio. Piedmont Investment invested in 13,674 shares. 20,609 are owned by Raymond James Advsrs Inc. Impact Advsr Lc reported 34,777 shares stake. 73,513 are held by Great West Life Assurance Can. Cap Mngmt accumulated 269,625 shares. Victory Cap Management reported 3,199 shares. Sg Cap Mgmt Llc, a Illinois-based fund reported 280,945 shares. Profund Advisors Ltd holds 5,756 shares or 0.02% of its portfolio. Hood River Mgmt Ltd Liability Company holds 1.2% or 386,661 shares in its portfolio. Timpani Cap Mngmt Ltd reported 87,508 shares. Partner Fund Lp reported 977,313 shares. Rhumbline Advisers holds 154,092 shares or 0.02% of its portfolio. Cornerstone accumulated 30 shares. Goldman Sachs, New York-based fund reported 285,335 shares.

Analysts expect Merit Medical Systems, Inc. (NASDAQ:MMSI) to report $0.50 EPS on July, 22.They anticipate $0.07 EPS change or 16.28 % from last quarter’s $0.43 EPS. MMSI’s profit would be $27.51 million giving it 28.43 P/E if the $0.50 EPS is correct. After having $0.37 EPS previously, Merit Medical Systems, Inc.’s analysts see 35.14 % EPS growth. The stock decreased 1.58% or $0.91 during the last trading session, reaching $56.86. About 230,781 shares traded. Merit Medical Systems, Inc. (NASDAQ:MMSI) has risen 9.46% since July 14, 2018 and is uptrending. It has outperformed by 5.03% the S&P500.

Merit Medical Systems, Inc. (NASDAQ:MMSI) Ratings Coverage

Among 2 analysts covering Merit Medical Systems (NASDAQ:MMSI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Merit Medical Systems has $73 highest and $69 lowest target. $71’s average target is 24.87% above currents $56.86 stock price. Merit Medical Systems had 4 analyst reports since February 27, 2019 according to SRatingsIntel. The firm has “Buy” rating by Barrington given on Wednesday, February 27. On Wednesday, February 27 the stock rating was maintained by Needham with “Buy”.

Merit Medical Systems, Inc. designs, develops, makes, and markets medical products for interventional and diagnostic procedures worldwide. The company has market cap of $3.13 billion. The company's Cardiovascular segment offers cardiology and radiology devices for diagnosing and treating coronary arterial, peripheral vascular, and other non-vascular diseases; and embolotherapeutic products. It has a 72.71 P/E ratio. It also provides vascular access products; guide wires, inflation devices, and diagnostic catheters for use in angiography procedures; therapeutic infusion systems and safety products; drainage catheters and drainage access products, support catheters, vascular retrieval devices, and dialysis access products; and embosphere microspheres and delivery systems, and microcatheters.

More notable recent Merit Medical Systems, Inc. (NASDAQ:MMSI) news were published by: which released: “Merit Medical Systems beats by $0.03, beats on revenue – Seeking Alpha” on February 26, 2019, also with their article: “Health Care Sector Update for 04/24/2019: ANTM,PRPO,MMSI – Nasdaq” published on April 24, 2019, published: “Is Merit Medical Systems, Inc. (MMSI) A Good Stock To Buy? – Yahoo Finance” on June 27, 2019. More interesting news about Merit Medical Systems, Inc. (NASDAQ:MMSI) were released by: and their article: “Merit Medical (MMSI) Q4 Earnings & Revenues Surpass Estimates – Nasdaq” published on February 28, 2019 as well as‘s news article titled: “Here is Why Growth Investors Should Buy Merit Medical (MMSI) Now –” with publication date: May 02, 2019.

Merit Medical Systems, Inc. (NASDAQ:MMSI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.